Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps - CNBC

1. Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps  CNBC
2. What Novo Nordisk’s disappointing trial results mean for the obesity drug market  STAT
3. 'A worst case scenario for Novo': Read the market reaction to CagriSema trial  Reuters.com
4. There’s a New Obesity King  The Wall Street Journal